Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
NCT00444795 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 520
Last updated 2017-02-01
Summary
To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)
Conditions
Interventions
- DRUG
-
Sunitinib malate
Sunitinib : dosing not pre-determined
- DRUG
-
Sunitinib malate
Sunitinib : dosing not pre-determined
- DRUG
-
sunitinib malate
Sunitinib : dosing not pre-determined
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2015-03-31
- Completion
- 2015-03-31
Countries
- South Korea
Study Locations
More Related Trials
-
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
NCT00411151 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
NCT04409223 ·Status: TERMINATED ·Phase: PHASE3
-
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
NCT00793871 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
NCT00672594 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
NCT02691793 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
NCT00748358 ·Status: COMPLETED ·Phase: PHASE2
-
A Bioequivalence Study of Sunitinib Malate Capsules.
NCT05800106 ·Status: COMPLETED ·Phase: PHASE1
-
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
NCT07096609 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
NCT00716625 ·Status: COMPLETED
-
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
NCT00417885 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Sunitinib Malate in Refractory Germ Cell Tumors
NCT00912912 ·Status: TERMINATED ·Phase: PHASE2
-
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
NCT00684645 ·Status: COMPLETED
-
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
NCT01731925 ·Status: UNKNOWN ·Phase: PHASE2
-
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma
NCT01441661 ·Status: COMPLETED
-
Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
NCT01019798 ·Status: UNKNOWN ·Phase: PHASE2
-
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
NCT00137449 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
NCT01286896 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
NCT00471276 ·Status: COMPLETED ·Phase: PHASE2
-
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
NCT02450123 ·Status: COMPLETED ·Phase: NA
-
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
NCT00465179 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Patients With Bulky GIST Using Sunitinib
NCT01054911 ·Status: TERMINATED ·Phase: NA
-
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
NCT00979329 ·Status: COMPLETED
-
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
NCT00535379 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT01525550 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
NCT00570882 ·Status: COMPLETED ·Phase: PHASE2